Biotech Breakthrough as Huntington's Disease Treatment Shows Promising Results
TL;DR
UniQure's experimental gene therapy, AMT-130, showed promising results in slowing Huntington's disease progression by 75%, leading to a over 240% surge in its stock price and plans to seek FDA approval by 2026, offering hope for a disease-modifying treatment.
- Biotech Stock Launches 220% On Possible Huntington's Cure Investor's Business Daily
- Huntington's disease successfully treated for first time BBC
- Huntington’s disease treated successfully for first time in UK gene therapy trial The Guardian
- UniQure ‘Exceeds Expectations’ in Much-Anticipated 3-Year Huntington’s Readout BioSpace
- UniQure's therapy slows Huntington's disease progression in trial; Shares more than triple CNBC
Want the full story? Read the original reporting
Read on Investor's Business Daily